Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRC-Wound
- Development stage
- Preclinical
- Lead developer
- Britecyte
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional, Subcutaneous
01
Overview
BRC-Wound is an investigational, off-the-shelf allogeneic engineered adipose therapy being developed by Britecyte. It consists of processed human adipose-derived stem cells and tissue designed to restore structure and function in chronic ischemic wounds, particularly in patients with peripheral arterial disease (PAD). The therapy utilizes Britecyte's proprietary processing technology, which removes immunogenic components to enable allogeneic transplantation while preserving the native tissue architecture, including intact adipocytes and extracellular matrix. This provides a structural scaffold and angiogenic signaling to promote tissue remodeling, vascularization, and wound healing.
Beyond the preview
Go deeper on BRC-Wound.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRC-Wound.